Misplaced Pages

Osanetant

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 00:31, 12 August 2011 (Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per [[Misplaced Pages:WikiProject Chemicals/Chembox validation|Chem/Drugbox). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 00:31, 12 August 2011 by CheMoBot (talk | contribs) (Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per [[Misplaced Pages:WikiProject Chemicals/Chembox validation|Chem/Drugbox)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound
Osanetant
Clinical data
ATC code
  • none
Identifiers
IUPAC name
  • N-(1-{3-propyl}-4-phenylpiperidin-4-yl]-N-methylacetamide
CAS Number
PubChem CID
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.233.307 Edit this at Wikidata
Chemical and physical data
FormulaC35H41Cl2N3O2
Molar mass606.625 g/mol g·mol
3D model (JSmol)
SMILES
  • CC(=O)N(C)C1(CCN(CC1)CCC2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl)C5=CC=CC=C5
  (verify)

Osanetant (SR-142,801) is a neurokinin 3 receptor antagonist developed by Sanofi-Synthélabo, which is being researched for the treatment of schizophrenia. It was the first non-peptide NK3 antagonist developed in the mid-1990s, and has still not made it to market, although clinical trials are continuing. Another potential application for osanetant is in the treatment of drug addiction, as it has been found to block the effects of cocaine in animal models.

References

  1. Kamali, F (2001). "Osanetant Sanofi-Synthélabo". Current opinion in investigational drugs (London, England : 2000). 2 (7): 950–6. PMID 11757797. {{cite journal}}: Unknown parameter |month= ignored (help)
  2. Emonds-Alt, X; Bichon, D; Ducoux, JP; Heaulme, M; Miloux, B; Poncelet, M; Proietto, V; Van Broeck, D; Vilain, P (1995). "SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor". Life sciences. 56 (1): PL27–32. PMID 7830490.
  3. Quartara L, Altamura M (2006). "Tachykinin receptors antagonists: from research to clinic". Current Drug Targets. 7 (8): 975–92. doi:10.2174/138945006778019381. PMID 16918326. Retrieved 2011-04-14. {{cite journal}}: Unknown parameter |month= ignored (help)
  4. Desouzasilva, M; Mellojr, E; Muller, C; Jocham, G; Maior, R; Huston, J; Tomaz, C; Barros, M (2006). "The tachykinin NK3 receptor antagonist SR142801 blocks the behavioral effects of cocaine in marmoset monkeys". European Journal of Pharmacology. 536 (3): 269–78. doi:10.1016/j.ejphar.2006.03.010. PMID 16603151. {{cite journal}}: Unknown parameter |month= ignored (help)
  5. Jocham, Gerhard; Lezoch, Katharina; Müller, Christian P.; Kart-Teke, Emriye; Huston, Joseph P.; De Souza Silva, M. AngéLica (2006). "Neurokinin receptor antagonism attenuates cocaine's behavioural activating effects yet potentiates its dopamine-enhancing action in the nucleus accumbens core". European Journal of Neuroscience. 24 (6): 1721–32. doi:10.1111/j.1460-9568.2006.05041.x. PMID 17004936. {{cite journal}}: Unknown parameter |month= ignored (help)

Template:Neuropeptide agonists and antagonists


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: